Introduction
Natural Killer (NK) cells are critical effectors in the innate immune response against cancer, virus-infected and other aberrant cells. [1] [2] [3] Their functional state, unlike that of T cells, does not depend on receptor rearrangement for antigen recognition. 4 Instead, NK function is under the fine control of several activating and inhibitory signals induced by the binding of various NK receptors to their corresponding ligands on target cells. 5 Inhibitory NK receptors include killer Ig-like receptors (KIRs) and C-type lectin NKG2A/E-CD94 heterodimers, which bind HLA class I molecules displayed on the surface of potential target cells. [6] [7] [8] Activating receptors include: the natural cytotoxicity receptors (NCRs) NKp46, 9,10 NKp44 11 and NKp30, 12 the ligands of which have not yet been identified; the C-type lectin NKG2D 13 receptor, which binds to MHC class-I chain-related molecule (MIC) 14 and UL-16-binding protein (ULBP), 15, 16 and activating KIRs. 17 Once activated, NK cells release granzymes and perforin to induce apoptosis of the target cells. [18] [19] [20] The graft-versus-leukemia (GvL) 21 effect mediated by donor-derived immune effectors early after hematopoietic stem cell transplantation (HSCT) may eradicate residual tumor cells and may be crucial in preventing disease relapse. Donor-derived NK cells typically undergo differentiation within 30 days 22 and might thus participate in an early GvL effect. In acute myeloid leukemia (AML), the contribution of NK cells to GvL has been strikingly shown in KIR-HLA-C mismatched haploidentical HSCT, where donor-derived NK alloreactive clones could eradicate residual blasts. 23, 24 In the non-haploidentical setting, no such alloreactive NK clones mediate post-transplant blast eradication and proper NK response to triggering ligands expressed on target cells is likely to play a central role in preventing disease escape from NK immune surveillance. In this context, efficient positive signaling from activating NK receptors is probably crucial. Previous studies focused on NK cells in AML have shown that altered NK activity and cytokine production in-vitro may associate to early relapse. 25 Moreover, it has been shown that the down-regulation of NCRs is common in AML and that this phenomenon may lead to defective anti-leukemic response.
In this study, we ex-vivo explored the function of early reconstituted NK cells following non-haploidentical HSCT. We show for the first time that NK degranulation may fluctuate between day 30 (D30) and day 60 (D60), undergoing a significant down-regulation specific to AML patients at D60. In addition, we show that in AML patients the expression levels of NKp46 and NKp30 are down-regulated at day 60. This phenotypic alteration is thus associated to NK loss of function. These data strongly suggest that donor-derived NK response against residual AML blasts may rapidly fall following non-haploidentical HSCT. AML-specific early NCR downregulation may affect post-HSCT NK function. Novel immunotherapy strategies to enhance post-HSCT NK function may therefore be important to control AML residual disease.
Materials and methods

Patients and donors
Thirty-five selected adults (median age 49 years; range 17-66 years) undergoing HSCT between January 2006 and August 2008 at the Institut Gustave Roussy were included in the study; written informed consent prior to inclusion. We excluded patients without full donor chimerism not to impair donor NK specific assessment. We included seventeen patients with AML and eighteen patients with non-AML hematological malignancies. An overview of the patients and their treatment details is given in Table 1 . All HSCT were non T cell-depleted. Six patients (nr. 9, 10, 17, 19, 27, 29) receiving a graft from unrelated donors were not fully HLA-matched (9/10). Patient nr.27 received two cord blood units from unrelated donors. No NK alloreactivity in the graft versus host direction was present. Samples from twelve donors were also available.
Collection of samples and PBMC isolation
Peripheral blood samples (30 ml) were collected 30 and 60 days after transplantation or immediately after if NK cell yield was inadequate for analysis. Immediately after collection, PBMC were isolated by Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradient centrifugation (931 g, 20 min). The isolated PBMC were washed once in 0.9% NaCl and resuspended in RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10% human serum (Institut Jacques Boy, Reims, France). 
CD107a degranulation assay
/CD56
þ NK cells were further characterized using the following R-phycoerythrin-coupled mAbs: NKp46 (IgG1), NKp44 (IgG1), NKp30 (IgG1), NKG2A (IgG2), KIR2DL1/S1 (IgG1), KIR2DL2-3/S2 (IgG1), CD16 (IgG1), CD69 (IgG1) (Immunotech) and NKG2D (IgG1) (R&D Systems, Abingdon, UK). Background levels were measured with isotype controls. For each sample, at least 3000 NK-gated events were acquired using the above mentioned flow cytometers. FlowJo V 8.8.5 (TreeStar, Ashland, OR, USA) was used to analyze all phenotypic data.
Characterization of serum cytokines Serum samples from 19 selected patients (including 8 AML and 11 non-AML) and 8 donors were decanted and stored at À80 1C for further analysis. IL-15 and TGF-b 1 (without prior ex-vivo activation of biologically inactive complex) levels were determined by ELISA (RayBiotech, Norcross, GA, USA). Levels of TNF-a, IFN-g, IL-2, IL-4, IL-6 and IL-10 were determined simultaneously using the Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit II (BD Bioscience, San Diego, USA). The minimum detectable doses of IL-15 and TGF-b1 are typically less than 3 pg/ ml and less that 80 pg/ml, respectively. The minimum detectable doses by CBA Th1/Th2 cytokine kit correspond to less than 10 pg/ml for IFN-g and less than 3 pg/ml for all the other cytokines.
Statistical analysis
Non parametric statistics were used to compare numbers and percentages of lymphocyte subsets, antigen expression levels on the surface of NK cells, degranulation and serum 
Results
Transplantation outcome
All patients were receiving CsA for post-HSCT GVHD prophylaxis or treatment at the time of sampling. After a median follow up of 299 days, seven patients died. Of those, five experienced an early relapse (within three months). Nine patients developed signs of acute and/or chronic GVHD (Table 1) .
Lymphocyte subset reconstitution following HSCT
The kinetics of reconstitution of lymphocyte subpopulations, including NK cells, was highly similar in AML and non-AML patients. Overall, the NK cell subpopulation was rapidly reconstituted after HSCT and absolute numbers of NK cells remained fairly constant between D30 and D60. The proportion of total lymphocytes accounted for by NK cells was significantly higher in patients than in donors (P-values for D30 and D60 were 0.005 and 0.006, respectively). NK cells were characterized by higher proportions of CD56 bright cells at both time points. The percentage of CD56 bright NK cells was highly variable from one patient to another. No correlation has been found between the frequency of such subset and NK cell degranulation in patients. CD16 was expressed by almost all donor NK cells, while recipients expressed significantly lower median levels at both time-points, indicating NK cell reconstitution (Table 2) . Both the absolute number of CD3 þ T cells (P-value for both D30 and D60 compared to donors was o0.0001) and the proportion of CD3 þ T cells accounting for total PB lymphocytes (P-values for D30 and D60, compared to donors were 0.007 and 0.005, respectively) were significantly lower in patients than in donors, resulting in a higher NK/T cell ratio in patients ( Table 2 ). The percentage of PB lymphocytes accounted for by T cells in patients on D60 was directly correlated with the T-cell content of the graft (P ¼ 0.03) (not shown). The median CD4 þ /CD8 þ T cell ratio in patients was 0.6 to 0.7 at both time-points.
The absolute number of CD3 þ /CD56 þ cells did not differ significantly between donors and patients, but these cells accounted for a higher proportion of lymphocytes in patients on D30 compared to donors. CD19 þ cell numbers were very low, both on D30 and D60 (Table 2 ).
Decreased NK cell degranulation potential in AML patients at D60 post-HSCT Ex-vivo assessment of NK cell cytolytic potential was performed using the degranulation test (Figure 1 þ cells %, AML and non-AML groups: 8.7 and 10.8 respectively; P-value NS). At D60, a significant NK functional difference between AML and non-AML patients was observed (median CD107a þ cells %, AML and non-AML groups: 6.4 and 14.9 respectively; P ¼ 0.01) (Figure 1a) . AML patients showed a significant NK Table 2 Lymphocyte subsets in patients and donors functional drop between D30 and D60 (P ¼ 0.05), while in non-AML patients the NK degranulation potential at D60 was comparable to the earlier time-point (P ¼ 0.48) (Figures 1a and b) . Accordingly, AML patients accounted for eight of the ten weakest percentages of CD107a NK cells following stimulation with K562 targets at D60. Of note, the patient (nr. 5) showing the most significant drop in degranulation potential relapsed at day þ 42 and eventually died three months after transplantation. No other tested variable apart from AML status (ageovs450 yrs, sex, complete remission vs non complete remission at HSCT, CD34 þ and CD3 þ administered cell doses above vs below median value, high dose vs reduced intensity conditioning regimens, absence vs administration of total body irradiation, and duration of aplasia above vs below median time) was found to differentially affect NK cell function at D60 as compared to D30. The NK cell degranulation range in the patient subgroup (n ¼ 6) with acute GVHD was wide (2.2-27.2%) at D60. In addition, we did not observe any direct or inverse correlation between the severity of GVHD and the degranulation values. Although limited, these data suggest that acute GVHD occurrence and the in-vitro response of early reconstituted resting NK cells against a susceptible tumor target are independent phenomena.
NKp30 and NKp46 down-regulation in AML patients
We investigated possible correlations between the decreased degranulation potential and the expression levels of receptors affecting NK lytic potential. Figure 2 summarizes the overall expression of NK cell activating receptors (Figures 2a-d The differential expression of NKp46, NKp30 and NKG2D activating receptors in the AML and non-AML groups is shown in Figure 3a . At D30, all three receptors were strongly expressed both in AML and non-AML patients. At D60, non-AML patients globally maintained high levels of NCR þ and NKG2D þ NK cells. Conversely, AML patients showed reduced percentages of NKp46 þ cells (P ¼ 0.02) and reduced NKp46 MFI ratio values (P ¼ 0.01). Moreover, the percentage of NKp30 þ cells was strongly decreased (P ¼ 0.00002) in the AML group (Figures 3a and b) . Finally, in both groups a reduced NKp30 MFI ratio was observed at D60, although this was only significant in non-AML patients (P ¼ 0.008; AML group: P ¼ 0.09). NKG2D percent expression tended to decrease at D60 in AML patients. This decrease did not reach statistical significance. No other tested receptors showed a fluctuating expression at D60 as compared to D30 in any group (not shown). We did not observe any increase of inhibitory NKG2A receptor in AML patients at D60 suggesting that this receptor is likely not involved in the down-regulation of NK function (not shown).
Persistent low IL-2 levels in AML patients along early NK reconstitution
To determine whether selected microenvironmental factors could account for the peculiar degranulation potential and receptor modulation of NK cells in AML patients, we determined the serum concentrations of the following eight cytokines in selected patients: IL-2, IL-4, IL-6, IL-10, IL-15, TNF-a, IFN-g and TGF-b 1 (Figure 4) . The levels of IL-6, IL-10 and IFN-g (Figures 4c, d and f) were high at D30 both in AML and in non-AML patients, increased compared to donors. At D60, the levels of these cytokines were decreased and comparable to donors. IL-4 levels were found to be lower than in donors in both AML and non-AML patients at D60 (P ¼ 0.05 and P ¼ 0.04 respectively) (Figure 4b ). Biologically active TGF-b 1 was below the detection threshold in patients at either time-point (Figure 4h) . Moreover, IL-15 was detected in the sera of most patients (median serum concentration [range], D30: 52.5 pg/ml [0-600]; D60: 22 pg/ml [0-900]), whereas it was below the detection threshold in donors (Figure 4e ). TNF-a levels were comparable in donors and patients (Figure 4g ). Interestingly, IL-2 was the only cytokine to show a clearly distinctive pattern in AML and non-AML patients (Figure 4a ). At D30, IL-2 was significantly decreased in the AML group compared to non-AML (P ¼ 0.003) and donors (P ¼ 0.05). At D60, IL-2 levels were lower than donors in both the AML (P ¼ 0.02) and the non-AML (P ¼ 0.004) group (Figure 4a ). NK cells of AML patients antigens. CD16 expression was reduced (h). NCRs and NKG2D are strongly expressed in almost all patients, including AML patients (a-d). The expression NKp46 is higher in patients than in donors at D30 and D60. The expression of NKG2A (g) was increased at both time points. KIR2DL1/S1 (e), KIR2DL2-3/S2 (f) is also shown. Bars showing significant differences are depicted.
only were thus persistently exposed to sub-optimal IL-2 levels during early reconstitution.
Discussion
We conducted a longitudinal study of a cohort of patients who received unmanipulated HSCT for AML (n ¼ 17) or non-AML hematological malignancies (n ¼ 18). Reconstituted NK cells likely originated not only from the engrafted hematopoietic progenitors, but also from the expansion of mature NK cells within the graft. Regardless of their origin, these cells may be involved in the early control of disease relapse. Early NK cell recovery may positively affect the outcome of transplantation, as suggested by the observation that NK numbers 4150/ml are associated with less relapses, no GVHD, less non-relapse mortality and improved survival in T cell depleted stem cell transplantation. 28 In our series, high numbers of circulating donor-derived NK cells were often found since D30 post-HSCT. Moreover, they represented a significant proportion of total lymphocytes throughout the first 60 days after HSCT in both the AML and the non-AML groups.
In addition to NK numbers, another important parameter to consider in evaluating NK-based anti-cancer immune surveillance could be the NK functional status. Among available functional tests, the degranulation test allows a reliable and repeatable ex-vivo assessment of the NK cell function, 29 obviating the need for cytokine modulation of cultured NK cells. As early as D30 post-HSCT, NK cells show a significant degranulation potential, at least as high as in tested donors, both in AML and non-AML patients. The up-regulation of CD69 on most NK cells following exposure to K562 targets further indicates that early reconstituted NK cells are prone to activation at D30 (not shown). The strong degranulation potential observed at D30 was not maintained at D60 by the AML group, where rather impressive functional drops were observed. This phenomenon was very common, being present in all but three AML patients.
At D30, NK cells expressed high levels of NKp46, NKp30 and NKG2D. The high expression of activating receptors may contribute to the efficient potential observed at this time-point. Percentages of NK cells expressing NKp46, NKp30 considerably reduced during the second month post-HSCT in AML patients. Delayed NCR expression has been previously reported, 30 but the specific down-regulation of these receptors along with NK reconstitution was not expected. In AML, the down-regulation of NCRs impairs the cytolytic function of NK cells and may affect patient survival. 26, 27 Likewise, we found here that NKp46 and NKp30 down-regulation at D60 is associated to a decreased ability of NK cells to undergo degranulation ex-vivo following exposure to K562 in AML patients. Changes in the functional state of NK cells following transplantation may have significant clinical consequences. 25 In our series, it is interesting that the AML patient with the most significant decrease in NK function (and of NKp30 and NKp46 expression levels) experienced an early relapse after transplantation. It cannot be excluded, however, that the relapse itself was indeed the cause of this observed impaired NK function.
Diverse microenvironmental factors are likely to be involved in controlling the functional state of NK cells. Several tested inflammatory cytokines (IL-6, IL-10, IFN-g) with potential impact on NK function were found to be higher in patients than in donors early after transplantation. IL-15 levels were detectable in patients but not in donors. It may promote the early recovery of NK cells after HSCT or favor the proliferation and survival of NK cells (as well as mature T cells).
31,32 IL-2 was increased in non-AML (not in AML patients) patients compared to donors. It may contribute to NK cell activation, up-regulating NCRs and lytic potential. Furthermore, IL-2 potentiates the cytotoxicity-enhancing action of IL-15. 33 TGF-b 1 specifically down-regulates NKp30 and NKG2D. 34 This cytokine was not detected in any serum tested, thus excluding its effect on receptor modulation. NK functional status and NCR expression levels may indeed depend on the overall balance of a network of soluble factors. Moreover, NKp30 displays diverse functions and is involved in dendritic cell (DC)/NK interactions, 35, 36 so that intercellular contact (e.g. with dendritic cells expressing the NKp30 ligand) rather than soluble factors might be the predominant mechanism specifically modulating NKp30 expression on reconstituted NK cells. Technical requirements as well as selection criteria account for the limited number of enrolled subjects. Nonetheless, we present several original observations that it would be important to repeat in wider studies. Additional studies should also analyze early post-transplant NK function in specific settings other than AML and address the impact of early NK function on HSCT outcome.
NK cells constitute a prominent lymphoid subset in the weeks following HSCT representing ideal targets for immunotherapeutic strategies (such as the administration of cytokines or mAbs blocking the interaction between class I HLA molecules on target cells and KIR2D/NKG2A receptors on NK effectors) potentially enhancing the GvL effect during this period. This study suggests that AMLs constitute a subgroup of hematologic malignancies that could particularly benefit from such adjuvant NK-based immunotherapeutic intervention.
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